Curiox is a bioinstrumentation company spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore. Curiox has become a leader in the development and commercialization of innovative assay platforms based on its expertise in surface chemistry and engineering. Curiox’s vision is to accelerate the progress of life sciences, drug discovery and diagnostics through the miniaturization and improved automation of bioassays.
DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange. The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.